Original BioMedicals Co., Ltd. is a biotechnology firm dedicated to advancing therapeutic solutions for critical medical demands, particularly by enhancing existing drug compounds and developing innovative delivery systems. Its pipeline includes Radprotect, an early-stage candidate engineered to shield against radiation exposure. Also under development is CCM-Ami, designed to safeguard healthy tissues from the harmful impacts of chemotherapy and radiation treatments, and GLP-1 CCM for managing type 2 diabetes. Established in 2011, the company operates from its headquarters in Taipei, Taiwan.